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Abstract 
Background: Novel therapeutic strategies are urgently needed to reduce relapse rates and enhance 
survival in Diffuse Large B-Cell Lymphoma (DLBCL) patients. CXCR4-overexpressing cancer cells are 
good targets for therapy because of their association with dissemination and relapse in R-CHOP treated 
DLBCL patients. Immunotoxins that incorporate bacterial toxins are potentially effective in treating 
haematological neoplasias, but show a narrow therapeutic index due to the induction of severe side 
effects. Therefore, when considering the delivery of these toxins as cancer therapeutics, there is a need 
not only to increase their uptake in the target cancer cells, and their stability in blood, but also to reduce 
their systemic toxicity. We have developed a therapeutic nanostructured protein T22-PE24-H6 that 
incorporates exotoxin A from Pseudomonas aeruginosa, which selectively targets lymphoma cells because 
of its specific interaction with a highly overexpressed CXCR4 receptor (CXCR4+) in DLBCL.  
Methods: T22-PE24-H6 cytotoxicity and its dependence on the CXCR4 receptor were evaluated in 
DLBCL cell lines using cell viability assays. Different in vitro experiments (mitochondrial membrane 
potential, Western Blot, Annexin V and DAPI staining) were conducted to determine T22-PE24-H6 cell 
death mechanisms. In vivo imaging and therapeutic effect studies were performed in a disseminated 
DLBCL mouse model that mimics organ infiltration in DLBCL patients. Finally, immunohistochemistry 
and histopathology analyses were used to evaluate the antineoplastic effect and systemic toxicity.  
Results: In vitro, T22-PE24-H6 induced selective cell death of CXCR4+ DLBCL cells by activating the 
apoptotic pathway. In addition, repeated T22-PE24-H6 intravenous administration in a CXCR4+ 
DLBCL-disseminated mouse model showed a significant reduction of lymphoma burden in organs 
clinically affected by DLBCL cells (lymph nodes and bone marrow). Finally, we did not observe systemic 
toxicity associated to the nanoparticle treatment in non-DLBCL-infiltrated organs.  
Conclusion: We have demonstrated here a potent T22-PE24-H6 antineoplastic effect, especially in 
blocking dissemination in a CXCR4+ DLBCL model without associated toxicity. Thereby, T22-PE24-H6 
promises to become an effective alternative to treat CXCR4+ disseminated refractory or relapsed 
DLBCL patients. 










Over the last years, different immunotoxins that 
incorporate highly cytotoxic bacterial proteins have 
entered clinical trials [1,2]. Only two of them, 
moxetumomab pasudotox-tdfk and tagraxofusp-erzs, 
obtained approval from the FDA for the treatment of 
hairy cell leukemia (HCL) and blastic plasmacytoid 
dendritic cell neoplasm (BPDCN), respectively, 
despite of the induction of severe side effects [3–5]. In 
fact, another immunotoxin (denileukin diftitox), 
approved to treat patients with cutaneous T-cell 
lymphoma (CTCL), was withdrawn from the market 
in 2014 because of life-threatening toxicity [6,7]. In this 
context, clinical translation of antibody drug 
conjugates (ADCs) and especially immunotoxins is 
being limited by severe off-target toxicity that leads to 
a narrow therapeutic window, most likely because 
only 0.001-0.01% of the injected dose (ID) reaches the 
tumor [8–10]. 
Aiming to enhance tumor cell uptake while 
reducing toxicity on normal tissues, we have 
developed a multimeric and self-assembled CXCR4- 
targeted protein-based nanoparticle for the selective 
delivery of toxins [11]. This approach increases toxin 
loading capacity and the number of targeting ligands 
per nanoparticle, leading to an increase in 
nanoparticle internalization and toxin delivery to 
target cancer cells through its specific receptor [12,13]. 
In our previous work, we have demonstrated that the 
targeted protein nanocarrier T22-GFP-H6 avoids renal 
filtration (>7 nm) and liver clearance, whereas most of 
the nanocarrier proteolytic metabolism occurs in 
tumor tissues [14,15]. In this context, we have 
generated a stable nanoparticle, T22-PE24-H6, that 
incorporates the toxin in a single polypeptide. 
T22-PE24-H6 specifically delivers a de-immunized 24 
kDa catalytic domain of Pseudomonas aeruginosa (PE) 
exotoxin A to the chemokine receptor CXCR4 
overexpressing (CXCR4+) cancer cells by interacting 
with its T22 ligand [11,16]. These cancer cells are 
relevant clinical targets since CXCR4 overexpression 
is associated with aggressiveness and dissemination 
in many solid and hematological cancers [17–21]. 
Indeed, T22-PE24-H6 could improve treatment 
outcomes in CXCR4+ diffuse large B-cell lymphoma 
(DLBCL) patients, because of their association with 
poor progression-free as well as overall survival in 
R-CHOP treated patients; and also because CXCR4+ 
DLBCL cells are responsible for relapse and resistance 
to R-CHOP [22–24]. Currently, no protein-based 
targeted therapeutic nanoparticle has been developed 
to treat disseminated or therapy-resistant DLBCL.  
Here, we determine the antineoplastic effect of 
the T22-PE24-H6 nanoparticle actively targeting 
CXCR4+ DLBCL cells to evaluate whether it could 
increase the therapeutic window of immunotoxins. 
Our approach is highlighted in Figure 1. Firstly, we 
evaluate the in vitro cytotoxicity of T22-PE24-H6 in 
different CXCR4+ DLBCL cell lines and its 
dependence on CXCR4 receptor expression. In 
addition, we analyze the cell death type induced by 
T22-PE24-H6 and, most importantly, we evaluate the 
in vivo T22-PE24-H6 antineoplastic effect in DLBCL- 
infiltrating organs, lymph nodes (LNs) and bone 
marrow (BM), and its systemic toxicity in a 
disseminated mouse model. This novel approach aims 
to increase the cure rates and reduce the toxicity in 
CXCR4+ DLBCL patients. 
Methods 
Production and purification of therapeutic 
T22-PE24-H6 polypeptidic nanoparticle 
All the details of T22-PE24-H6 nanoarchitecture 
and production were described in our previous work 
[11].  
Cell culture and cytotoxicity assays  
Human DLBCL cell lines (Toledo, SUDHL-6, 
U-2932 and SUDHL-2) were cultured at 37 ºC in a 5% 
CO2 humidified atmosphere. Toledo, SUDHL-6 and 
U-2932 cells were cultured in RPMI 1640 medium, and 
SUDHL-2 cells in IMDM medium. Culture media for 
all cell lines were supplemented with 10% FBS, 1% 
glutamine and 100 U/mL penicillin-streptomycin 
(Life Technologies). Toledo cells were purchased from 
ATCC, U-2932 and SUDHL-6 from DSMZ, and 
SUDHL-2 were kindly provided by Dr L. Pasqualucci 
(Columbia University, NY, USA).  
Moreover, the Luciferase plasmid (pPK-CMV- 
F3, Promokine) was transfected by electroporation 
(Nucleofector TM 2b Device, Lonza) into Toledo cells 
(Toledo-Luci cells). The expression of the Luciferase 
gene in transfected cells was detected by the IVIS 
Spectrum 200 Imaging System (PerkinElmer). Stable 
clones were obtained by selection in medium 
containing 0.2 mg/mL of geneticin (G418, Life 
Technologies) for a period of 10 weeks.  
In vitro T22-PE24-H6 cytotoxicity in DLBCL cells 
was evaluated measuring cell metabolic capacity 
using the colorimetric cell proliferation kit II (XTT, 
Roche Diagnostics). 30∙104 cells (Toledo, SUDHL-6, 
U-2932 and SUDHL-2) were seeded into 96‐well 
plates in 100 μL of media and incubated at 37 °C for 24 
h. Then, cells were exposed to different T22-PE24-H6 
concentrations (0.1-5 nM) or carbonate buffer (166 
mM NaCO3H pH=8) for 48 h and assessed for 
viability. The competitive assays were done by 
pre-incubating the cells with AMD3100 (ratio 
1T22-PE24-H6:10AMD3100). Fifty μL of the mixture 





XTT reagent were added to each well and, after 4 h 
incubation, cell viability was quantified by measuring 
the absorbance at 450 nm wavelength using a spectro-
photometer (BMG Labtech). Results were expressed 
as percentage of cell viability in relation to its buffer.  
Western blotting 
Toledo cells were treated with buffer or 5 nM 
T22-PE24-H6 for different time exposures (7, 15, 24 
and 48 h). Cells were washed twice with PBS and 
resuspended in lysis buffer. Then, the suspension was 
sonicated and rested for 20 min on ice. Cells were 
centrifuged for 10 min at 14000 rpm and 4 ºC. Protein 
concentration in supernatant was determined using 
the Bradford protein assay, according to the 
manufacturer’s instructions (BioRad). Cell lysates (50 
μg) were separated using 12-15% SDS-PAGE and 
transferred to a nitrocellulose blotting membrane (GE 
Healthcare life sciences). Membranes were blocked 
with 5% skim milk in TBST for 2 h at room 
temperature, and then incubated with primary 
antibodies, 1:2000 PARP (556494, BD), 1:1000 
caspase-3 (610322, BD) or 1:10000 GAPDH (MAB374, 
Millipore). Membranes were washed with TBST and 
then incubated with the appropriate secondary 
antibody (1:10000, Jackson Immune Research). 
Western blot visualization was performed using the 
SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Fisher Scientific) and the G:BOX iChemi XT 
Imaging System (Syngene).  
Cleaved PARP and active caspase-3 protein 
levels were quantified using the ImageJ software. The 
relative density of the protein bands was calculated 
dividing the percent value of each treated sample (7 h, 
15 h, 24 h and 48 h; 5 nM T22-PE24-H6) by the 
standard sample (Buffer). To get the normalized 
density value, the relative density of each sample lane 
was divided by the relative density of its loading 
control (GAPDH). 
Apoptosis assessment  
For the evaluation of JC-1 staining in control and 
apoptotic cells, the instruction manual of flow 
cytometry mitochondrial membrane potential detec-
tion kit (BD™ MitoScreen Kit) was followed. Results 
were analyzed by FACS Calibur flow cytometer and 
the Cell Quest Pro software (BD Biosciences).  
 Additionally, the number of cells undergoing 
apoptosis (early or late) was quantified using the 
Annexin V-FITC/propidium iodide (PI) detection kit 
(Merck Millipore), following the manufacturer’s 
instructions. Data were analyzed by MACSQuant 
analyzer flow cytometry using the MACS Quantify 
version 2.3 software (Miltenyi Biotec). 
 
 
Figure 1. Graphical image visualizing the highly selective targeting and high cytotoxicity induced by the T22-PE24-H6 nanoparticle on CXCR4+ cancer 
cells in a disseminated DLBCL mouse model. The image describes critical characteristics of the T22-PE24-H6 polypeptidic nanoparticle that leads to its high CXCR4+ 
DLBCL-cell uptake within LNs and BM. This nanoparticle reaches the neoplastic tissues without being proteolyzed in the liver or excreted by the kidneys. Once in the affected 
organ, T22-PE24-H6 interacts with the CXCR4 receptor in lymphoma cells, to induce its internalization by endocytosis and its traffic to Golgi and endoplasmic reticulum (ER). 
There, the PE24 toxin inactivates EF-2, which inhibits protein synthesis and consequently induces cancer cell death by apoptosis. BM: bone marrow; DLBCL: diffuse-large B-cell 
lymphoma; EF-2: elongation factor 2; LNs: lymph nodes; PE: Pseudomonas aeruginosa. 





DAPI staining  
Lymphoma cells were seeded at 3·105 cells/mL 
(6 mL) in a cell culture dish and incubated at different 
times (15, 24 and 48 h) with 5 nM T22-PE24-H6 
nanoparticle or buffer. Afterwards, cells were 
centrifuged at 400 g for 5 min, washed with PBS, 
centrifuged again, resuspended with 1 mL of 3.7% 
paraformaldehyde and fixed for 10 min at -20 ºC. 
Then, cells were washed, resuspended with ~10 µL of 
PBS and placed on a slide. Finally, slides were stained 
with DAPI mounting medium (Thermo Fisher 
Scientific) and visualized using a fluorescence micro-
scope (Olympus BX53, Olympus). Representative 
pictures were taken using an Olympus DP73 digital 
camera and processed with the cellSens Dimension 
1.9 software (Olympus) at 1000 magnifications.  
In vivo antineoplastic effect in a DLBCL 
disseminated mouse model  
Four-week-old female NOD-SCID mice were 
obtained from Charles River Laboratories (L-Abreslle, 
France), maintained in SPF conditions and housed 
with sterile food and water ad libitum. In vivo 
experiments were approved by the Hospital de Sant 
Pau Animal Ethics Committee. After one week in 
quarantine, mice were intravenously injected with 
luciferase-transfected Toledo cells (Toledo-Luci cells, 
20·106/200 µL) and divided randomly in two groups. 
Three days after cell injection, one group was 
administered intravenously with 166 mM NaCO3H 
pH 8 buffer (buffer-treated mice, n=9) and the second 
group with 5 µg of T22-PE24-H6 (T22-PE24-H6- 
treated mice, n=9). Both groups were injected three 
times per week for a total of thirteen doses. 
Lymphoma dissemination was monitored using 
bioluminescence imaging (BLI, total radiance 
photons) technique in the IVIS Spectrum (Perkin-
Elmer), once per week. Mice were anesthetized with 
3% isoflurane in oxygen and BLI was captured 5 min 
after intraperitoneal injection of firefly D-luciferin 
(2.25 mg/mouse, Perkin Elmer). Moreover, mouse 
body weight was registered twice a week until the 
end of the experiment.  
All mice were euthanized when the first mouse 
presented relevant signs of disease such as poor 
mobility or significant weight loss. At that day, the 
BLI of lymphoma-infiltrated organs, cervical and 
renal LNs as well as BM was analyzed ex vivo. Finally, 
all organs were collected and fixed in 4% 
formaldehyde for further histopathological or 
immunohistochemical evaluations. 
Cervical LNs size assessment 
Cervical LNs area was calculated for 18 cervical 
LNs in each group (buffer or T22-PE24-H6) using 
ImageJ software. Area ratio was calculated in relation 
to buffer-treated LNs.  
Histopathology and immunohistochemical 
staining 
All paraffin-embedded organs were stained with 
H&E to perform a complete histopathological analysis 
and a clinical pathologist supervised all samples for 
toxicity evaluation. To detect the presence of human 
B-cells and to quantitate the percentage of organ 
infiltration, we used immunohistochemistry (IHC) 
staining with an antibody anti-human CD20cy (clone 
L26, Dako). Firstly, 5 and 27 low power fields at 100 
magnifications were taken for LNs and BM, 
respectively, in each mice group (buffer or T22-PE24- 
H6). Secondly, the area occupied by B cells in each 
organ was selected and the percentage of CD20+ cells 
was quantified using the cellSens Dimension 1.9 
software (Olympus). 
IHC staining was performed in a DAKO 
Autostainer Link48 (Agilent) following the 
manufacturer’s instructions. Representative pictures 
were taken using an Olympus DP73 digital camera 
and processed with the cellSens Dimension 1.9 
software (Olympus) at 200 or 400 magnifications.  
Statistical analysis 
All values are expressed as mean ± standard 
error (SE). Differences between groups were analyzed 
using the Mann-Whitney U test and were considered 
statistically significant at p≤0.05. Statistical 
calculations were performed using SPSS software v21. 
Results 
CXCR4-dependent antineoplastic effect of 
T22-PE24-H6 in DLBCL cell lines 
Levels of CXCR4 membrane expression in the 
four tested DLBCL cell lines have been previously 
reported [15,25]. Toledo cells showed the highest 
levels of CXCR4 expression followed by U-2932, 
SUDHL-6, whereas SUDHL-2 did not express 
detectable levels of the receptor in their membrane. 
Thus, we firstly evaluated the sensitivity of these cell 
lines to the T22-PE24-H6 nanoparticle and its possible 
correlation with their CXCR4 membrane expression. 
To that aim, in vitro cytotoxic assays were performed 
after 48 h exposure to different nanoparticle concen-
trations (0.1-5 nM). Results showed that T22-PE24-H6 
therapeutic nanoparticle, at low concentrations, had 
an antineoplastic effect in Toledo, SUDHL-6 and 
U-2932 cells, which express high levels of CXCR4 
receptor in their membrane (CXCR4+ DLBCL cell 
lines). In contrast, exposure of SUDHL-2 cells 
(CXCR4- DLBCL cell line) to this nanoparticle did not 
induce any cytotoxic effect (Figure 2A). 






Figure 2. T22-PE24-H6 induces cytotoxicity in CXCR4+ DLBCL cell lines. (A) In vitro cell viability (%) of different DLBCL cell lines after exposure to T22-PE24-H6 
(0.1-5 nM) for 48 h. (B) Competition cell viability assays done by 1 h pre-treatment with 50 nM AMD3100 followed by the addition of 5 nM T22-PE24-H6 during 48 h exposure 
in DLBCL cell lines. Toledo, SUDHL-6 and U-2932 are CXCR4+ DLBCL cell lines, whereas the SUDHL-2 cell line does not express CXCR4. Experiments were performed in 
biological triplicates and results expressed as mean ± SE. *p≤0.05. 
 
On the other hand, we studied whether the cell 
death induced by the T22-PE24-H6 nanoparticle in 
CXCR4+ DLBCL cells was dependent on its 
internalization through the CXCR4 receptor. In this 
context, competition assays were performed by 
pre-incubating the cells with AMD3100, a CXCR4 
antagonist, 1 h before the addition of T22-PE24-H6, at 
a molar ratio of 10:1. Cell exposure with AMD3100 
blocked nanoparticle binding to CXCR4 and 
produced a complete reversion of cell viability 
(~100%) in all three CXCR4+ DLBCL cell lines (Figure 
2B).  
Hence, T22-PE24-H6 displays a potent in vitro 
antineoplastic effect only in the DLBCL cell lines that 
overexpress CXCR4, since endocytosis of the 
nanoparticle is exclusively mediated through the 
CXCR4 receptor. 
T22-PE24-H6 induces apoptosis-mediated cell 
death in CXCR4+ DLBCL cells  
After demonstrating the cytotoxic effect of the 
nanoparticle in CXCR4+ DLBCL cells, we performed 
different assays to identify the mechanism of cell 
death induction. Firstly, we analyzed whether 
depolarization of mitochondria was involved as one 
of the first events in the cell death mediated by 
T22-PE24-H6 nanoparticle. Thus, we monitored 
mitochondrial membrane potential by JC-1 dye. We 
observed that after 15 h exposure of Toledo cells to 5 
nM T22-PE24-H6, 44.6±5.3% of cells showed 
depolarization of mitochondrial membrane and this 
percentage increased up to 65.5±7.1% at 48 h (Figure 
3A-B). Secondly, to evaluate whether the nanoparticle 
induced cell death through the apoptotic pathway, we 
performed the AnnexinV-FITC/PI test. We 
determined that the percentage of cells in early 
apoptosis increased from 29.0±4.4% at 15 h to 
35.5±8.1% at 24 h, decreasing considerably afterwards 
at 48 h because of a concomitant increase in late 
apoptosis from 22.0±3.8% at 24 h to 62.4±1.3% at 48 h 
(Figure 3C-D). Moreover, we used western blot to 
evaluate the proteolysis of pro-caspase-3 and PARP as 
markers of apoptosis induction. The exposure of 
CXCR4+ DLBCL cells to T22-PE24-H6, during the 15 h 
to 48 h exposure period, caused a decrease of the 
pro-caspase-3 and PARP expression together with the 
increase of both cleaved caspase-3 and cleaved PARP 
that occurred at the final stage of cell death (Figure 
3E-F). To further confirm apoptosis as the cell death 
mechanism, we performed nuclear DAPI staining and 
observed the expected increase of apoptotic bodies 
over time (Figure 3G). 
On this basis, the cell death mechanism induced 
by T22-PE24-H6 in Toledo CXCR4+ DLBCL cell line is 
mediated by apoptosis activation.  
T22-PE24-H6 antineoplastic effect in the 
bioluminescent CXCR4+ DLBCL disseminated 
mouse model  
Afterwards, we also determined the 
antineoplastic effect of T22-PE24-H6 in a 
bioluminescent CXCR4+ DLBCL disseminated mouse 
model. This animal model, which was generated by 
the intravenous injection of Toledo-Luci cells and 
described in detail in our previous work, shows 
CXCR4 overexpression in all organs infiltrated by 
lymphoma cells [15]. Here, we started the intravenous 
administration of 5 µg T22-PE24-H6 or buffer (3 
times/week and a total of 13 doses) in this mouse 
model 3 days after the injection of Toledo-Luci cells. 
Lymphoma dissemination was monitored until the 
end of the experiment by capturing the BLI emitted by 
Toledo-Luci cells using the IVIS Spectrum (Figure 
4A). We observed a lower total flux of BLI during the 
whole follow-up period in nanoparticle-treated mice 
than in buffer-treated mice. Indeed, this low BLI 





signal in nanoparticle-treated mice indicated a 
reduction of lymphoma-cell dissemination, which 
was already significant at day 14 after cell injection 
and became highly significant at days 21, 28 and 33 
compared to buffer-treated animals (Figure 4B-C). 
Finally, no significant differences in mouse body 
weight were found between groups (Figure 4D). 
 
 
Figure 3. Apoptosis induction after T22-PE24-H6 exposure in CXCR4+ Toledo DLBCL cell line. (A) Representative dot-plot, showing the percentage of cells 
undergoing mitochondrial membrane depolarization for this particular replicate (mean percentage is described in the Results text), and (B) quantification of loss of JC-1 red 
fluorescence (%) in Toledo cells after 15 h, 24 h or 48 h exposure to buffer or 5 nM T22-PE24-H6 nanoparticle. (C) Representative dot-plot, showing percentages related to this 
replicate, and (D) quantification of viable cells (V), at early or late apoptosis (EA or LA), using Annexin V-FITC/PI test, after 15 h, 24 h and 48 h exposure to 5 nM T22-PE24-H6 
or buffer in Toledo cells. (E) Toledo cells treated with buffer or 5 nM T22-PE24-H6 for 7 h, 15 h, 24 h and 48 h, and subjected to Western blot using PARP and caspase-3 
antibodies. GAPDH antibody is used as an internal control. (F) Relative protein intensity quantitation of cleaved caspase-3 and cleaved PARP expression normalized to GAPDH. 
(G) DAPI staining of Toledo cells after exposure to buffer or 5 nM T22-PE24-H6 for 15 h, 24 h and 48 h. Original magnification x1000. Experiments were performed in biological 
triplicates and results expressed as mean ± SE. *p≤0.05. 






Figure 4. In vivo and ex vivo BLI analysis of Toledo-Luci disseminated mice treated with buffer or T22-PE24-H6 therapeutic nanoparticle. (A) Experimental 
design followed along the in vivo experiment. (B) Representative images of mice with disseminated lymphoma registered by IVIS Spectrum (BLI signal) at day 21, 28, and 33 after 
Toledo-Luci cells IV injection in mice treated with buffer or T22-PE24-H6. (C) BLI quantification over the experimental time in mice treated with buffer (n=9) or T22-PE24-H6 
(n=9). (D) Body weight of mice treated with buffer or T22-PE24-H6 during the treatment period. (E) Ex vivo BLI quantitation (left) and representative images (right) of 
lymphoma-infiltrated organs (cervical LNs, renal LNs and BM) for both groups at the end of the experiment. Results are expressed as mean ± SE. BLI: bioluminescence imaging 
(total flux); BM: bone marrow; IV: intravenous; LNs: lymph nodes; *p≤0.05; **p≤0.01; ***p≤0.005. 





T22-PE24-H6 nanoparticle antineoplastic 
effect in CXCR4+ DLBCL-infiltrated organs in 
the disseminated mouse model 
At the day of euthanasia (day 34), when the 
lymphoma was totally disseminated in buffer-treated 
mice, we analyzed ex vivo the bioluminescence 
emitted by the lymphoma-infiltrated organs in both 
groups (buffer or T22-PE24-H6). We detected a highly 
significant antineoplastic effect in the cervical LNs in 
T22-PE24-H6 treated mice, observing a 14 fold 
reduction (0.27±0.09E5) compared to the BLI emitted 
in buffer-treated mice (3.76±0.97E5). Moreover, the 
reduction of lymphoma infiltration was observed also 
in the renal LNs and BM, displaying 5 and 6 times less 
BLI total flux in the animals treated with the 
therapeutic nanoparticle (1.07±0.11E4 and 0.38±0.09E6, 
respectively) compared to the buffer group (5.64± 
1.68E4 and 2.29±0.81E6, respectively) (Figure 4E).  
Thus, a significant reduction in lymphoma 
dissemination in T22-PE24-H6-treated mice compared 
to mice treated with buffer is observed in the organs 
infiltrated by CXCR4+ DLBCL cells (LNs and BM). 
T22-PE24-H6 reduces the load of CXCR4+ 
DLBCL lymphoma cells in affected organs  
Furthermore, we observed macroscopic 
differences in the cervical LNs size between mice 
treated with nanoparticle or buffer at the end of the 
experiment. In this context, the cervical LNs size in 
nanoparticle-treated mice was significantly reduced 
more than halfway (47.7±3.2%) compared to the 
buffer-treated mice (100±4.4%) (Figure 5A). This size 
reduction was related to the lower number of 
Toledo-Luci cells infiltrating the cervical LNs, as we 
demonstrated by IHC using the human B-cell CD20 
marker. In buffer-treated mice we found that 94.24± 
0.47% of cells within cervical LNs were Toledo-Luci 
cells (CD20+), whereas the percentage of CD20+ cells 
diminished significantly in the nanoparticle-treated 
mice, reaching only 7.53±9.23% (Figure 5B and E). 
Accordingly, T22-PE24-H6 also induced antineo-
plastic effect in renal LNs, since the percentage of 
lymphoma cells was reduced from 69.89±5.01% in 
mice treated with buffer to 11.31± 10.83% after 
repeated doses of the nanoparticle (Figure 5C and E). 
Regarding the BM, we also observed a significant 
reduction of the Toledo-Luci cells after T22-PE24-H6 
treatment. We quantified 71.62±2.50% CD20+ cells 
infiltrating the BM in buffer-treated mice, a 
percentage that was reduced to 45.13±3.25% after 
T22-PE24-H6 treatment (Figure 5D-E).  
Definitely, and consistently with BLI detection, 
we demonstrate the antineoplastic effect of T22-PE24- 
H6 in CXCR4+ DLBCL-infiltrated organs by mea-
suring CD20+ cells in a disseminated mouse model.  
Lack of toxicity by T22-PE24-H6 in the 
non-infiltrated-DLBCL organs  
Finally, once we demonstrated the T22-PE24-H6 
effectiveness to CXCR4+ lymphoma cells we analyzed 
its harmlessness in non-affected tissues. We did not 
find any alteration produced by the T22-PE24-H6 
nanoparticle at the macroscopic level (data not 
shown). At microscopic level (Figure 6), we analyzed 
the histopathology (H&E staining) of non-infiltrated 
lymphoma tissues in order to carefully assess the 
possible toxicity of the nanoparticle. Regarding the 
spleen, we observed the same hematopoietic tissue 
prevalence in buffer-treated than in nanoparticle- 
treated mice. Pancreas and heart tissues were also as 
healthy in nanoparticle-treated as buffer-treated 
animals. Furthermore, we did not observe congestion, 
edema or intraalveolar hemorrhage in the lung tissue 
in nanoparticle-treated mice. In the liver tissue of 
nanoparticle-treated animals, the hepatocytes did not 
lose their architecture and we did not observe 
steatosis or any sign of histological alteration. Finally, 
the glomerulus and surrounding renal tubules in 
nanoparticle-treated mice were clearly visible without 
cytoplasmic vacuolation or eosinophilic protein 
accumulation. Thus, we did not find any 
morphological changes associated with nanoparticle 
administration that could indicate toxicity in 
non-infiltrated organs. 
To sum up, the therapeutic nanoparticle, at the 
chosen administration conditions, does not induce 
off-target toxicity in the Toledo-Luci disseminated 
mouse model. 
Discussion 
The administration of the T22-PE24-H6 
therapeutic nanoparticle at low doses shows a potent 
antineoplastic effect in a disseminated DLBCL mouse 
model without associated toxicity. Both outcomes are 
achieved by the selective elimination of CXCR4+ 
DLBCL cells, which leads to the control of DLBCL 
growth and dissemination. This is based on the 
observation of a lower percentage of CD20+ cells 
within CXCR4+ DLBCL infiltrated organs in 
nanoparticle-treated animals, while observing no 
histopathological alteration in non-affected normal 
organs.  
These findings are consistent with our recent 
demonstration of a high uptake for the T22-GFP-H6 
nanocarrier in subcutaneous (SC) tumors generated 
by CXCR4+ lymphoma cells (86.1% of the total ID) and 
its low or negligible biodistribution to non-DLBCL 
affected organs (13.9% of the total ID) [15]. This high 
uptake may improve the performance of ADCs, for 
which less than 1% ID reaches the tumor, while most 
of the ID is catabolized by the liver and the 





reticuloendothelial system [26,27]. An improved 
T22-GFP-H6 uptake was also shown in CXCR4+ 
lymphoma cells affecting LNs and BM in a 
disseminated DLBCL mouse model [15]. Indeed, the 
T22-PE24-H6 nanoparticle size (60.17 nm) and the 
sinusoidal capillaries present in DLBCL niches (LNs 
and BM) can profit from the enhanced permeability 
and retention (EPR) effect [11,28–30]. Thus, the high 
T22-PE24-H6 nanoparticle tumor uptake may take 
advantage of the EPR effect, the discontinued endo-
thelia in the relevant clinical organs and the active 
targeting to high CXCR4 overexpressing DLBCL cells. 
 
 
Figure 5. Macroscopic and microscopic analysis of T22-PE24-H6 antineoplastic effect in the Toledo-Luci disseminated mouse model. (A) Cervical LNs 
images in buffer and T22-PE24-H6-treated mice (above) and quantification of cervical LNs area (n=18/group), expressed as area ratio, for both groups (below). (B-D) 
Representative images of H&E staining and CD20 IHC (human DLBCL cells) of lymphoma-infiltrated organs (cervical LNs, renal LNs and BM) in buffer and T22-PE24-H6-treated 
mice. Original magnification x200 and insets at x400. (E) Quantitation of the percentage of CD20+ cells in cervical LNs (n=5 fields/group), renal LNs (n=5 fields/group) and BM 
(n=27 fields/group) tissues for both mouse groups. Results are expressed as mean ± SE. BM: bone marrow; H&E: hematoxylin and eosin; IHC: immunohistochemistry; LNs: lymph 
nodes; ***p≤0.005. 






Figure 6. Toxicity analysis of T22-PE24-H6 treatment in the Toledo-Luci disseminated mouse model. Histopathology analysis (H&E staining) of non-infiltrated 
organs (spleen, pancreas, heart, lungs, liver and kidneys) in mice treated with buffer or T22-PE24-H6. Original magnification x200 and insets at x400. H&E: hematoxylin and eosin. 
 
 We argue that the potent antineoplastic effect 
observed in the absence of toxicity in the 
disseminated mouse model relates also to the 
compactness of the self-assembled nanoparticle 
structure, composed of fusion-protein monomers that 
incorporate the toxin in a single polypeptide chain, to 
prevent leakage in the bloodstream [11,31]. Regarding 
this issue, we recently determined that the 
T22-PE24-H6 protein integrity, and its full-length size 
(29.2 kDa), is maintained in human blood for at least 
10 days [32]. Moreover, this exceptional multimeric 
single polypeptide, which recruits all required 
functional domains, allows nanoparticle purification 
in a single step, avoiding the need to chemically 
conjugate the cytotoxic payload to the carrier while 
facilitating its fabrication in endotoxin-free bacterial 
systems [33,34]. 
Apart from the polypeptidic nanoparticle 
structure, the constitutive overexpression of the 
CXCR4 receptor in many available DLBCL cell lines 
[23,35] and around 30-50% of malignant B-cell 
lymphocytes derived from DLBCL patients [23,36] 
allows to achieve a highly selective elimination of 
aggressive-lymphoma cells by this CXCR4-targeted 
nanoparticle. Going deeper into the mechanism, 
T22-PE24-H6 internalizes in CXCR4+ tumor cells by 
endocytosis. Then, the furin-cleavage sites, inserted 
between the T22 ligand and the functional PE24 toxin, 
permit toxin intracellular activation in the cytosol, 
inducing protein synthesis inhibition, which finally 
leads, as we show here, to the induction of cell death 
by apoptosis [11,37,38]. Interestingly, this mechanism 
of action permits the killing of dividing and 
non-dividing cancer cells, differing from the cell 
cycle-dependent killing induced by genotoxic 
chemotherapy [2]. Consistently, using the same 
approach, our group previously proved T22-PE24-H6 
capacity to selective eliminate CXCR4+ colorectal 
cancer cells in a SC tumor model [11,16].  
Regarding the use of PE exotoxin A in current 
cancer therapies, PE38-based immunotoxins have 
been tested in clinical trials against different 
hematological cancers [1], being one of them already 
approved to treat relapsed or refractory HCL patients 
[3]. However, due to the use of an unstable linkage, 
the toxin can be prematurely released from the carrier 
antibody while is circulating in the bloodstream, 
which together with the immunogenicity induced by 
the toxin itself limit the dosage that can be used to 
treat patients [9,39,40]. For instance, the US 
FDA-approved moxetumomab pasudotox-tdfk 
immunotoxin causes infusion reactions, edema, fever 
and anemia, among other symptoms, in relapsed or 
refractory HCL patients. Some of the patients also 
experience dose-limiting toxicities, mainly hemolytic 
uremic syndrome and capillary leak syndrome [3]. 
Probably this dosage limitation may underlie the 
observation that PE38-based immunotoxins targeting 
different surface markers or receptors expressed in 
lymphoma cells (e.g. CD22 or CD25) could not induce 
either partial or complete remissions in non-Hodgkin 
lymphoma patients [41,42]. Currently, many PE38 





derivative-based immunotoxins incorporate sequence 
modifications to reduce their immunogenicity while 
preserving their efficacy. In this context, PE24 
appeared to be less immunogenic than PE38 because 
of the elimination of several immunogenic B-cell and 
T-cell epitopes. Accordingly, we incorporated the 
PE24 toxin to our nanoparticle, as other authors did 
the same replacement to generate immunotoxins (e.g. 
PE24-based HA22-LR-8MIT) [7,43].  
In conclusion, our novel delivery approach uses 
a multimeric single polypeptide-based nanoparticle 
that promises to improve the narrow therapeutic 
window observed in immunotoxin therapies, 
especially by reducing the toxicity. Moreover, our 
results validate CXCR4 overexpressing cells as a 
relevant clinical target for treating refractory or 
relapsed DLBCL patients that overexpress CXCR4. 
Ultimately, future experimental work will dictate the 
level of relevance of the multiple factors that 
distinguish protein-nanoparticles from immuno-
toxins, a requirement to improve immunotoxin or 
nanoparticle targeting selectivity, which for most 
current nanoparticles appear to be still limited [44]. 
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